FindTrial
Sign In

Ocular complications, lagophthalmos, and dry eye in preseptal versus pretarsal botulinum toxin injection in benign essential blepharospasm

Ocular complications, lagophthalmos, and dry eye in preseptal versus pretarsal botulinum toxin injection in benign essential blepharospasm

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
TCTR
Registry ID
TCTR20190807005
Enrollment
40
Registered
2019-08-07
Start date
2019-08-08
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Blepharospasm Blepharospasm&#44

Interventions

Preseptal botulinum toxin injection in one eye (inject at preseptal area of orbicularis oculi muscle&#44
near lid about 10 mm),Pretarsal botulinum toxin injection in another eye (inject at pretarsal area of orbicularis oculi muscle&#44
adjacent to lid)
Experimental Procedure/Surgery,Experimental Procedure/Surgery
Preseptal botulinum toxin injection ,Pretarsal botulinum toxin injection

Sponsors

Ratchadapiseksompoh fund, Chulalongkorn university
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Age ≥ 18 years old, and were diagnosed as blepharospasm by a neuroophthalmologist or neurologist.

Exclusion criteria

Exclusion criteria: Prior botulinum toxin injection less than 3 months, allergy to botulinum toxin

Design outcomes

Primary

MeasureTime frame
Ocular complications, lagophthalmos, Dry eye At 1 and 3 months after injection Margin to reflex distance, lagophthalmos, tears break up time, ocular surface staining—

Secondary

MeasureTime frame
Efficacy At 1 and 3 months after injection Jankovic rating scale—

Countries

Thailand

Contacts

Public ContactLalita Sanguandikul

Faculty of medicine, Chulalongkorn university

Nattiezmdcu@gmail.com0641656934

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026